Psychiatric manifestations in dementia

CONTINUUM Lifelong Learning in Neurology

Volumn 13, Issue 2, 2007, Pages 165-179

  Apostolova, Liana G ^a   Cummings, Jeffrey L ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Neurology ^*

^c Alzheimer's Disease Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; OLANZAPINE; PLACEBO; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

AGITATION; ALZHEIMER DISEASE; ANXIETY; APATHY; BEHAVIOR DISORDER; CAPGRAS SYNDROME; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DEATH; DEGENERATIVE DISEASE; DELUSIONAL MISIDENTIFICATION; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DYSPHORIA; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM; FALLING; FRONTOTEMPORAL DEMENTIA; GAIT DISORDER; HALLUCINATION; HUMAN; HYPERTENSION; ILLUSION; IRRITABILITY; LEWY BODY; MENTAL DISEASE; MULTIINFARCT DEMENTIA; NEUROPSYCHIATRY; OBSESSIVE COMPULSIVE DISORDER; PARAMNESIA; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; TACHYCARDIA;

EID: 34247254370     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000267240.99874.8d     Document Type: Review

References (28)

1. ▶ Alexopoulos GS, Meyers BS, Young RC, et al. "Vascular depression" hypothesis. Arch Gen Psychiatry 1997;54:915-922. A comprehensive overview of the link between cerebrovascular disease, depression, and dementia.
2. ▶ Apostolova LG, Cummings JL. Neuropsychiatric features of dementia with Lewy bodies. In: O'Brien J, Ames D, McKeith I, Chiu E, eds. Dementia with Lewy bodies. London: Taylor & Francis, 2005:73-94. A comprehensive overview of neuropsychiatric symptoms in dementia with Lewy bodies (DLB).
3. ▶ Ballard C, McKeith I, Harrison R, et al. A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr 1997;9:381-388. This study provides detailed description of visual hallucinations in DLB.
4. ▶ Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;25:CD003476. Comprehensive meta-analysis of the randomized controlled clinical trials of the atypical antipsychotics in Alzheimer's dementia.
5. ▶ Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000a;157:4-15. A comprehensive review of the cognitive and behavioral effects of cholinesterase inhibitors (AChEIs) in Alzheimer's dementia.
6. ▶ Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol Aging 2000b;21: 845-861. A review of the cognitive and behavioral heterogeneity in Alzheimer's disease (AD), linking recent advances in clinical epidemiology, molecular biology, genetics, and neuroimaging.
7. ▶ Cummings JL. The neuropsychiatry of Alzheimer's disease and related dementias. London: London Informa Healthcare, 2003. A comprehensive textbook on neuropsychiatric symptoms in AD, FTD, vascular dementia (VaD), DLB, Parkinson's disease, and Creutzfeldt-Jakob disease.
8. ▶ Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314. The study describes the Neuropsychiatric Inventory, an informant-based measure for behavioral and neuropsychiatric symptoms in patients with dementia.
9. ▶ Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63. Post hoc analysis of the behavioral effects of memantine on neuropsychiatric symptoms in moderate to severe Alzheimer's dementia.
10. ▶ Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology 2004;62:1199-1201. This study reports the prevalence of neuropsychiatric symptoms in MCI from baseline data of the Investigation in the Delay to Diagnosis of Alzheimer's Disease with Exelon (InDDEx) study. Patients with neuropsychiatric symptoms had significantly greater global, cognitive, and functional impairment.
11. ▶ Hodges JR, Miller B. The neuropsychology of frontal variant frontotemporal dementia and semantic dementia. Introduction to the special topic papers: part II. Neurocase 2001;7:113-121. A comprehensive review of the clinical, neuropsychiatric, neuropsychological, and imaging findings in frontotemporal dementia (FTD).
12. ▶ Hou CE, Carlin D, Miller BL. Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates. Can J Psychiatry 2004;49:164-171. A comprehensive overview of the following tau- and synuclein-associated dementias: FTD, corticobasal degeneration, progressive supranuclear palsy, DLB, and multiple system atrophy.
13. ▶ Hwang TJ, Masterman DL, Ortiz F, et al. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 2004;18:17-21. A tertiary center prevalence study of the neuropsychiatric symptoms in mild cognitive impairment (MCI) and mild AD.
14. ▶ Leroi I, Voulgari A, Breitner JC, et al. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry 2003;11:83-91. Epidemiologic community-based study of psychosis in Alzheimer's and VaD.
15. ▶ Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475-1483. Epidemiologic community-based study on the prevalence of neuropsychiatric symptoms in MCI and Alzheimer's dementia.
16. ▶ Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 2002;52:243-252. A comprehensive review of depressive symptoms in AD and the available therapeutic options.
17. ▶ Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-714. Epidemiologic community-based study on the prevalence of neuropsychiatric symptoms in elderly persons who are demented.
18. ▶ McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the dementia with Lewy bodies Consortium. Neurology 2005;65:1863-1872. Recently revised criteria for the clinical and pathologic diagnosis of DLB.
19. ▶ McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58: 1803-1809. Consensus clinical and neuropathologic criteria for the diagnosis of FTD.
20. ▶ McPherson S, Fairbanks L, Tiken S, et al. Apathy and executive function in Alzheimer's disease. J Int Neuropsychol Soc 2002;8:373-381. Cross-sectional study examining the relationship between apathy and neuropsychological test performance in Alzheimer's dementia.
21. ▶ Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135. A tertiary center prevalence study of the behavioral abnormalities in patients with AD of mild, moderate, and advanced severity.
22. ▶ Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004;61:1290-1293. This prospective cohort study reports that patients with MCI and depression are at an increased risk for developing Alzheimer's dementia relative to those without depression.
23. ▶ Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001a;58:1985-1992. A detailed review of the concept of MCI.
24. ▶ Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001b;56:1133-1142. AAN practice guideline for the diagnosis of MCI (Appendix C).
25. ▶ Rippon GA, Crook R, Baker M, et al. Presenilin 1 mutation in an African American family presenting with atypical Alzheimer dementia. Arch Neurol 2003;60:884-888. Case report of the clinical and behavioral manifestations in a patient with presenilin-1 mutation.
26. ▶ Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608. Concise review of the efficacy of antipsychotics, antidepressants, mood stabilizers, and AChEIs in the treatment of neuropsychiatric symptoms in patients with dementia.
27. ▶ Tang-Wai D, Lewis P, Boeve B, et al. Familial frontotemporal dementia associated with a novel presenilin-1 mutation. Dement Geriatr Cogn Disord 2002;14:13-21. Case report of the clinical and behavioral manifestations in a patient with presenilin-1 mutation.
28. ▶ Tiraboschi P, Salmon DP, Hansen LA, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 2006;129: 729-735. Recent postmortem study comparing the usefulness of early-onset visual hallucinations, extrapyramidal symptoms, and visuospatial impairment for differentiating DLB from Alzheimer's dementia.